Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome

Thrombosis and Haemostasis

Volumn 99, Issue 4, 2008, Pages 782-783

  Grimaldi, David ^a   Bartolucci, Pablo ^a   Gouault Heilmann, Michele ^a   Martin Toutain, Isabelle ^b   Khellaf, Mehdi ^a   Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; RITUXIMAB;

AGED; ARTICLE; BLOOD CLOTTING; CASE REPORT; ESOPHAGITIS; ESOPHAGUS ULCER; GASTROSCOPY; HEMATEMESIS; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOPLASTIN TIME; TREATMENT FAILURE; VON WILLEBRAND DISEASE;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PARAPROTEINEMIAS; TREATMENT FAILURE; VON WILLEBRAND DISEASE;

EID: 43749095917     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-07-0456     Document Type: Article

References (11)

1. Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol 2005; 66: 422-430.
2. Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-4428.
3. Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14: 401-436.
4. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
5. Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-3629.
6. Coleman R, Favaloro EJ, Soltani S, et al. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting autoantibodies to von Willebrand factor. J Thromb Haemost 2006; 4: 2085-2088.
7. Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004; 92: 666-667.
8. Michiels JJ, Berneman Z, Gadisseur A, et al. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 2006; 32: 577-588.
9. Macik BG, Gabriel DA, White GC, et al. The use of high-dose intravenous gammaglobulins in acquired von Willebrand's syndrome. Arch Pathol Lab Med 1988; 112: 143-146.
10. Agarwal N, Klix MM, Burns CP. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Ann Intern Med 2004; 141: 83-84.
11. Scrobohaci ML, Daniel MT, Levy Y, et al. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993; 84: 471-475. 784-786